Quick Answer
XTL BIOPHARMACEUTICALS LTD reported Total Assets of $8.55 million for fiscal year 2024.
XTL BIOPHARMACEUTICALS LTD — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Assets | $5.84M +140.8% |
$2.43M -42.0% |
$4.19M -36.7% |
$6.62M +1.8% |
$6.50M -9.8% |
$7.21M -15.9% |
| R&D Expense | $98.0K +216.1% |
$31.0K +3.3% |
$30.0K +0.0% |
$30.0K -21.1% |
$38.0K +8.6% |
$35.0K -7.9% |
| Gross Profit | $3.0K | — | — | — | — | — |
- XTL BIOPHARMACEUTICALS LTD reported Total Assets of $8.55 million for fiscal year 2024.
- XTL BIOPHARMACEUTICALS LTD showed an increase of +46.4% in Total Assets compared to the prior fiscal year.
- XTL BIOPHARMACEUTICALS LTD reported R&D Expense of $98.0 thousand for fiscal year 2024.
- XTL BIOPHARMACEUTICALS LTD showed an increase of +216.1% in R&D Expense compared to the prior fiscal year.
- XTL BIOPHARMACEUTICALS LTD reported Gross Profit of $3.0 thousand for fiscal year 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: